LivaNova (NASDAQ: LIVN) — Company Overview, News & Financial Data
LivaNova is a medical technology company developing solutions in cardiovascular and neuromodulation to enhance patient outcomes.
LivaNova
LivaNova (NASDAQ:LIVN) is a global medical technology company focused on developing innovative solutions that improve patient outcomes and enhance lives. The company operates two primary business segments: Cardiovascular and Neuromodulation. In the cardiovascular realm, LivaNova is dedicated to advancing technology for cardiac surgery, including heart valve therapy, and cardiopulmonary solutions. On the neuromodulation front, the company is a pioneer in offering devices designed to treat epilepsy and depression, aiming to address some of the most challenging areas of unmet medical needs. With a commitment to clinical excellence and innovation, LivaNova's projects and objectives are centered around transforming the standard of care for patients around the world, driving sustainable growth, and extending its reach into new markets to improve more lives with their medical technologies.
Snapshot
Operations
Products and/or services of LivaNova
- Vagus Nerve Stimulation (VNS) Therapy Systems for drug-resistant epilepsy and treatment-resistant depression, offering a unique non-pharmacological treatment option.
- Perceval sutureless aortic valve, providing a less invasive option for surgical aortic valve replacement in patients with aortic valve disease.
- SenTiva generator and VNS Therapy Programming System, an advanced option for managing seizures in drug-resistant epilepsy, allowing for tailored treatment.
- LifeSPARC advanced circulatory support system, designed for rapid deployment in patients needing circulatory support during cardiac procedures or acute heart failure.
- Solox cardiovascular oxygenator, a key component in cardiopulmonary bypass surgery, supporting patients' lungs and heart during complex cardiac surgeries.
- Membrane oxygenators, which play a crucial role in extracorporeal membrane oxygenation (ECMO) for patients with life-threatening heart and lung conditions.
LivaNova executive team
- Vladimir A. MakatsariaCEO & Director
- Alex ShvartsburgChief Financial Officer
- Natalia Sergeyevna KozminaChief Human Resources Officer
- Ahmet TezelChief Innovation Officer
- Lindsey LittleVP & Chief Accounting Officer
- Briana GotlinVice President of Investor Relations
- Anne M. LiddyChief Legal Officer
- Deanna WilkeVice President of Corporate Communications
- Philip KowalczykChief Strategy & Corporate Development Officer
- Paul R. BuckmanPresident of Advanced Circulatory Support & GM of Transcatheter Mitral Valve Replacement
Latest news about LivaNova
LivaNova delivers Q3 revenue of $393.1M, up 9.9%
United StatesLivaNova posts impressive 10.8% revenue increase
United StatesLivaNova beats estimates in Q1 as FDA approval for sleep apnea device bolsters outlook
United StatesLivaNova shares rise on double-digit revenue growth and significant medicare hike
United States
Key financials
Reported results for LivaNova , in USD.
- Market cap
- 4.4B
- Revenue (TTM)
- 1.5B
- P/E ratio
- 23.7
- EPS (diluted, TTM)
- 3.4
- Dividend yield
- —
- Profit margin
- 12.8%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 1.4B | 199.4M | -242.5M | |
| 1.3B | 129.1M | 63.2M | |
| 1.2B | -68.5M | 17.5M | |
| 1B | -76.8M | -86.2M |